In this continuation of the roundtable series on acute myeloid leukemia (AML), experts delve deeper into the evolving treatment landscape, focusing on the transformative role of targeted therapies. Led by Amer M. Zeidan, MBBS, of Yale School of Medicine, the discussion highlights emerging novel agents and their potential to refine personalized treatment strategies. The panel examines the mechanisms, clinical applications, and challenges of incorporating these innovations into AML care.
Precision Medicine in AML: An Abundance of Options
By Amer Zeidan, MBBS, MHS, Harry Erba, MD, Courtney DiNardo, MD, MSCE, Maximilian Stahl, MD - Last Updated: December 31, 2024Post Tags:ASH 2024: AML
Related Posts
A UC researcher secures $500K+ in grants to explore RAS inhibitors as potential treatments for acute myeloid leukemia.
Immunotherapy is transforming lymphoma treatment, reducing chemo reliance, and improving long-term outcomes.
FDA shifts to real-time FAERS reporting, aiming to boost transparency in drug safety but raising concerns on data use.
While azacitidine plus venetoclax is a feasible treatment option, it did not improve patients outcomes.
In a narrative review Dr. Krina Patel participated in and describes in this interview, myeloma experts engaged this question.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.